Background: Prophylaxis with factor (F) VIII is considered the optimal treatment for managing
hemophilia A patients without inhibitors. Objectives: To compare the efficacy of two …

Factor replacement therapy for the treatment of moderate to severe haemophilia A and B
can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor …

Summary Background: Prophylactic factor (F) VIII has been shown to reduce bleeds and
arthropathy in patients with severe hemophilia A. Objectives: Assuming that the trough FVIII …

Introduction We previously showed that pharmacokinetic‐guided prophylaxis (PKP) allows
the dosing interval to be extended while maintaining a specific trough level. However, the …

Background: Hemarthroses in severe hemophilia precipitate physical, psychosocial and
financial difficulties. Objective: To compare the effects of secondary prophylaxis with on …

A four-decade clinical experience and recent evidence from randomised controlled studies
definitively recognised primary prophylaxis, ie the regular infusion of factor concentrates …

Background: Hemophilic patients with factor VIII (FVIII) and FIX inhibitors suffer from frequent
bleeding episodes and reduced quality of life. Objectives: To evaluate whether secondary …

Background The benefits of routine prophylaxis vs. on-demand treatment with factor VIII
products have not been evaluated in controlled clinical trials in older patients with …

Replacement therapy or prophylaxis, has become the standard of care for the treatment of
severe haemophilia A. To describe bleeding patterns in children, adolescents and adults on …

Prophylaxis is widely recommended for the management of severe haemophilia A. Adoption
of this approach has varied from country to country, and notably in the US prophylaxis is …